摘要
背景:大麻的治疗效果自古以来就很出名。内源性大麻素系统(ECS)调节存在着越来越多与人类肿瘤发生相关的调制的证据。 目的:考虑到内皮细胞对免疫细胞调节的重要作用,本研究旨在总结出现过的有关的大麻素受体(CBR)和大麻素配体作用于血液系统恶性肿瘤中的表达。 结论:大多数大麻的行为对造血系统恶性细胞介导的主要规律很有潜力,作为细胞增殖和凋亡的诱导和抑制非凋亡性细胞程序性死亡已记录在册了。大麻素配体激活细胞生存的基本途径,如ERK、JNK、p38 MAPK以及诱导体外半胱天冬酶合成等。这些数据强烈被推荐并证实了大麻素配体的生物利用度和phytocannabinoid作用于神经的属性。初步的抗肿瘤作用及其相对缺乏的重要副作用,使内皮细胞治疗血液系统恶性肿瘤成为一种很有前途的治疗目标。
关键词: 大麻;大麻受体;内源性大麻素系统;血液系统恶性肿瘤;白血病;淋巴瘤。
Current Medicinal Chemistry
Title:Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Volume: 23 Issue: 22
Author(s): Constantinos Giaginis, Eleftheria Lakiotaki, Penelope Korkolopoulou, Konstantinos Konstantopoulos, Efstratios Patsouris and Stamatios Theocharis
Affiliation:
关键词: 大麻;大麻受体;内源性大麻素系统;血液系统恶性肿瘤;白血病;淋巴瘤。
摘要: Background: The therapeutic properties of cannabinoids are well-known since ancient years. Growing evidence exist on endocannabinoid system (ECS) modulation related with human tumorigenesis.
Objective: Taking into account the substantial role of ECS on immune cell regulation, the present review is aimed to summarize the emerging evidence concerning cannabinoid receptor (CBR) expression and cannabinoid ligand effects on haematological malignancies.
Conclusions: Most of cannabinoid actions, mainly CB2R-mediated against haematopoietic malignant cells, seem promising, as inhibition of cell proliferation and apoptosis and paraptosis induction have been documented. Cannabinoid ligands appear to activate rudimentary pathways for cell survival, such as ERK, JNK, p38 MAPK, and to induce caspase synthesis, in vitro. Such data are strongly recommended to be confirmed by in vivo experiments with emphasis on cannabinoid ligands’ bioavailability and phytocannabinoid psychotropic properties. The preliminary antitumoral ECS effects and their relative lack of important side effects render ECS a promising therapeutic target for the treatment of haematological malignancies.
Export Options
About this article
Cite this article as:
Constantinos Giaginis, Eleftheria Lakiotaki, Penelope Korkolopoulou, Konstantinos Konstantopoulos, Efstratios Patsouris and Stamatios Theocharis , Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?, Current Medicinal Chemistry 2016; 23 (22) . https://dx.doi.org/10.2174/0929867323666160530144934
DOI https://dx.doi.org/10.2174/0929867323666160530144934 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Hypericin and its Derivatives Act as Radiosensitizing Agents That Can Inhibit Tumor Initiating Cell Viability
Clinical Cancer Drugs The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design Editorial (Hot Topic: Therapeutic Potential of Fetal Mesenchymal Stem Cells)
Current Stem Cell Research & Therapy